CRIS Current Research Information System

BRANDI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.290
AS - Asia 15.960
EU - Europa 10.547
AF - Africa 896
SA - Sud America 861
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 11
AN - Antartide 1
Totale 45.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.042
VN - Vietnam 4.468
SG - Singapore 4.415
CN - Cina 3.818
GB - Regno Unito 2.278
IT - Italia 1.762
DE - Germania 1.316
SE - Svezia 1.232
HK - Hong Kong 1.008
IN - India 729
FR - Francia 708
RU - Federazione Russa 613
BR - Brasile 594
IE - Irlanda 568
CH - Svizzera 464
UA - Ucraina 337
NL - Olanda 312
KR - Corea 304
FI - Finlandia 299
JP - Giappone 249
ZA - Sudafrica 229
BD - Bangladesh 215
CI - Costa d'Avorio 192
TG - Togo 179
EE - Estonia 160
CA - Canada 137
SC - Seychelles 137
ID - Indonesia 108
JO - Giordania 105
AR - Argentina 102
PH - Filippine 92
AT - Austria 90
BG - Bulgaria 89
TH - Thailandia 70
NG - Nigeria 66
BE - Belgio 63
IQ - Iraq 60
MX - Messico 56
PL - Polonia 53
TR - Turchia 50
GR - Grecia 40
TW - Taiwan 40
CL - Cile 39
PK - Pakistan 38
EC - Ecuador 37
ES - Italia 34
MY - Malesia 29
CO - Colombia 27
SA - Arabia Saudita 27
PY - Paraguay 24
HR - Croazia 22
IR - Iran 22
UZ - Uzbekistan 21
LT - Lituania 20
RO - Romania 20
AU - Australia 19
VE - Venezuela 18
MA - Marocco 15
PS - Palestinian Territory 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
CR - Costa Rica 12
PE - Perù 12
ET - Etiopia 11
LB - Libano 11
TN - Tunisia 11
CZ - Repubblica Ceca 10
KZ - Kazakistan 10
PT - Portogallo 10
DZ - Algeria 9
JM - Giamaica 8
KE - Kenya 8
NP - Nepal 8
AZ - Azerbaigian 7
DK - Danimarca 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
SI - Slovenia 6
SV - El Salvador 6
AL - Albania 5
GT - Guatemala 5
HN - Honduras 5
HU - Ungheria 5
UY - Uruguay 5
IL - Israele 4
NO - Norvegia 4
OM - Oman 4
PR - Porto Rico 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
AO - Angola 3
BO - Bolivia 3
GE - Georgia 3
LK - Sri Lanka 3
LV - Lettonia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
Totale 45.538
Salva come PNG Salva come JPEG
Città #
Singapore 3.035
Southend 1.998
Ashburn 1.637
Chandler 1.329
Fairfield 1.287
San Jose 1.140
Hong Kong 948
Ho Chi Minh City 916
Dong Ket 832
Hanoi 802
Santa Clara 744
Dallas 693
Princeton 634
Houston 605
Wilmington 600
Hefei 592
Woodbridge 578
Seattle 537
Beijing 526
Dublin 518
Boardman 480
Bern 438
Cambridge 424
Bologna 387
Ann Arbor 371
Lauterbourg 313
New York 287
Los Angeles 282
Council Bluffs 280
Helsinki 243
Seoul 234
Tokyo 215
Nanjing 210
Westminster 202
Abidjan 192
Jacksonville 192
Lomé 179
Padova 171
Berlin 152
Buffalo 131
Milan 131
Jinan 129
Da Nang 122
Redondo Beach 122
San Diego 120
Haiphong 117
Frankfurt am Main 115
Menlo Park 112
Amman 102
Medford 99
Saint Petersburg 96
Guangzhou 94
Shenyang 92
Redmond 88
Shanghai 86
Sofia 85
São Paulo 84
Changsha 81
Rome 79
Hebei 77
Turin 77
Chicago 68
Jakarta 68
Florence 66
Nanchang 63
Brussels 58
Mülheim 57
Bengaluru 56
London 55
Nuremberg 55
Tianjin 53
Munich 52
Toronto 52
Vienna 51
Jiaxing 50
Orem 48
Zhengzhou 46
Abeokuta 45
Des Moines 43
Hangzhou 43
San Francisco 41
Can Tho 40
Phoenix 40
Amsterdam 39
Montreal 39
Yubileyny 39
Hải Dương 37
Redwood City 37
Biên Hòa 36
Brooklyn 35
Dearborn 35
Lappeenranta 35
Olalla 34
Warsaw 34
Ninh Bình 33
Norwalk 33
Pune 33
The Dalles 32
Kuban 31
Bremen 30
Totale 29.184
Salva come PNG Salva come JPEG
Nome #
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 400
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 398
Adjuvant treatment in biliary tract cancer 345
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 304
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 303
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 284
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 281
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 262
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 262
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 260
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 260
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 256
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 252
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 250
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 249
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 249
An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer 246
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 243
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 243
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 236
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 234
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 226
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 226
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 223
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 222
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 221
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 219
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 219
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. 217
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 215
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 215
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 214
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 213
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 213
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 211
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 210
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 210
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 209
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 209
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 209
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 208
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 208
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 207
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 205
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 205
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 205
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 204
Bone metastases in biliary cancers: A multicenter retrospective survey 202
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 202
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 201
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 200
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 200
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 197
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 197
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 197
In Reply 195
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 188
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 187
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 186
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 185
Treatment of colorectal cancer liver metastases 184
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 181
Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. 180
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 180
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 180
Cholangiocarcinoma: Epidemiology and risk factors 180
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 179
A multicenter survey on second-line chemotherapy for advanced biliary tract cancer 179
Second-line chemotherapy in patients with biliary tract cancer. 179
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 179
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 179
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 178
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 177
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 176
Breast carcinoma presenting as linitis plastica 176
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 174
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 174
Interactions between commensal bacteria and gut sensorimotor function in health and disease. 173
Cholangiocarcinoma: From risk to prevention? 173
BIFIDOBACTERIACEAE IN THE ACHLORIDRIC STOMACH 171
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. 171
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 170
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 170
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 168
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 168
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 168
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 167
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study 167
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 166
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 166
Bifidobacteriaceae usually colonize human hypochloridric stomach 166
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 166
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 165
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 165
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement 164
null 164
Totale 20.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.340 0 0 0 0 0 0 0 0 0 0 0 1.340
2021/20225.060 418 190 243 327 379 227 167 286 483 313 1.168 859
2022/20236.072 659 808 312 673 401 445 192 349 979 214 423 617
2023/20241.591 194 268 113 136 113 331 73 83 51 103 58 68
2024/20256.410 253 1.041 643 502 1.034 304 444 173 104 424 280 1.208
2025/202617.094 1.542 1.476 1.892 1.169 1.655 886 1.786 785 3.275 1.382 685 561
Totale 46.599